Pick 2–10 funds, stocks or ETFs to see their returns, risk, costs and highlights on one page
| Fund | ||||||||
|---|---|---|---|---|---|---|---|---|
| AZN.L | +2.24% | +7.83% | +11.77% | +16.76% | +10.46% | +3.26% | +13.06% | +45.62% |
| SCBIHEALT(SSFE) | +11.47% | +2.56% | +6.82% | +8.66% | +11.98% | +22.08% | +15.62% | +19.73% |
| SCBRMGHC | +10.03% | +2.73% | +5.09% | +7.13% | +4.42% | +13.92% | +19.29% | +40.77% |
| LHHEALTH-DSSF | +12.97% | +3.28% | +6.17% | +10.68% | +10.49% | +18.79% | +18.80% | +16.61% |
* Fewer than 12 months: the year the fund started reporting NAV, or the current year
Counts only the top holdings with available data, not the whole portfolio · Pick a pair below for details
Excludes AZN.L: money market or bond funds, or no holdings data yet
| SCBRMGHC | LHHEALTH-DSSF | |
|---|---|---|
| Held by both | ||
 Eli Lilly and Co | 9.53% | 9.14% |
 Johnson & Johnson | 7.71% | 9.43% |
 Unitedhealth Group | 4.23% | 6.16% |
 AstraZeneca | 3.68% | 3.72% |
 Novartis | 2.71% | 4.20% |
 Roche | 2.66% | 5.15% |
 Merck & | 2.33% | 6.22% |
| Only in SCBRMGHC | ||
 ABBVIE | 4.89% | N/A |
 Thermo Fisher | 3.32% | N/A |
 argenx | 2.43% | N/A |
| Only in LHHEALTH-DSSF | ||
 Vertex Pharmaceuticals | N/A | 3.66% |
 Gilead Sciences | N/A | 3.61% |
 Bristol-Myers Squibb Co | N/A | 2.80% |
30 Dec 2025 → 2 Nov 2026
| Fund | Return per year | Volatility per year | Sharpe |
|---|---|---|---|
| LHHEALTH-DSSF | +12.97% | 16.02% | 0.81 |
| SCBIHEALT(SSFE) | +11.47% | 17.39% | 0.66 |
| SCBRMGHC | +10.03% | 16.76% | 0.60 |
| AZN.L | +2.24% | 29.38% | 0.08 |
Sharpe here = annual return ÷ annual volatility, without deducting the risk-free rate, calculated from NAV over the selected period · Periods shorter than 1 year use the cumulative return instead of the annual return
| Drag a column header to reorder | AZN.L | SCBIHEALT(SSFE) | SCBRMGHC | LHHEALTH-DSSF |
|---|---|---|---|---|
Fund details | ||||
| Fund size | N/A | 10.11 million | 2,408 million | 0.49 million |
| Inception date | N/A | 29 Jun 2021 | 6 Nov 2015 | 29 Sep 2021 |
| Master fund | N/A | BNP Paribas Funds Health Care Innovators | Janus Henderson Global Life Sciences Fund | AB International Health Care Portfolio |
| Dividend policy | N/A | Pays | Does not pay | Pays |
Risk and currency hedging | ||||
| Risk level | N/A | 7 | 7 | 7 |
| Hedging policy | N/A | Hedged at the manager's discretion | Almost fully hedged | Hedged at the manager's discretion |
| Share hedged | N/A | 82.39% | 99.36% | 80.26% |
Minimum purchase and redemption | ||||
| First purchase | N/A | 1 THB | 1,000 THB | No minimum |
| Subsequent purchase | N/A | 1 THB | 1,000 THB | No minimum |
| Redemption (amount) | N/A | No minimum | 1,000 THB | No minimum |
| Redemption (units) | N/A | No minimum | No minimum | No minimum |
| Balance (amount) | N/A | No minimum | 1,000 THB | No minimum |
| Balance (units) | N/A | No minimum | No minimum | No minimum |
Order cut-off and redemption payment | ||||
| Buy before | N/A | 15:30 | 15:30 | 14:00 |
| Redeem before | N/A | 15:30 | 15:30 | 14:00 |
| Redemption paid | N/A | T+4 | T+5 | T+4 |
